These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
348 related articles for article (PubMed ID: 12468433)
1. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Mizuki M; Schwable J; Steur C; Choudhary C; Agrawal S; Sargin B; Steffen B; Matsumura I; Kanakura Y; Böhmer FD; Müller-Tidow C; Berdel WE; Serve H Blood; 2003 Apr; 101(8):3164-73. PubMed ID: 12468433 [TBL] [Abstract][Full Text] [Related]
2. RGS2 is an important target gene of Flt3-ITD mutations in AML and functions in myeloid differentiation and leukemic transformation. Schwäble J; Choudhary C; Thiede C; Tickenbrock L; Sargin B; Steur C; Rehage M; Rudat A; Brandts C; Berdel WE; Müller-Tidow C; Serve H Blood; 2005 Mar; 105(5):2107-14. PubMed ID: 15536149 [TBL] [Abstract][Full Text] [Related]
3. Targeted inhibition of FLT3 overcomes the block to myeloid differentiation in 32Dcl3 cells caused by expression of FLT3/ITD mutations. Zheng R; Friedman AD; Small D Blood; 2002 Dec; 100(12):4154-61. PubMed ID: 12393674 [TBL] [Abstract][Full Text] [Related]
4. Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction. Tickenbrock L; Schwäble J; Wiedehage M; Steffen B; Sargin B; Choudhary C; Brandts C; Berdel WE; Müller-Tidow C; Serve H Blood; 2005 May; 105(9):3699-706. PubMed ID: 15650056 [TBL] [Abstract][Full Text] [Related]
5. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Mizuki M; Fenski R; Halfter H; Matsumura I; Schmidt R; Müller C; Grüning W; Kratz-Albers K; Serve S; Steur C; Büchner T; Kienast J; Kanakura Y; Berdel WE; Serve H Blood; 2000 Dec; 96(12):3907-14. PubMed ID: 11090077 [TBL] [Abstract][Full Text] [Related]
7. Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPalpha expression. Zheng R; Friedman AD; Levis M; Li L; Weir EG; Small D Blood; 2004 Mar; 103(5):1883-90. PubMed ID: 14592841 [TBL] [Abstract][Full Text] [Related]
9. Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041 [TBL] [Abstract][Full Text] [Related]
10. Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor. Grundler R; Thiede C; Miething C; Steudel C; Peschel C; Duyster J Blood; 2003 Jul; 102(2):646-51. PubMed ID: 12663439 [TBL] [Abstract][Full Text] [Related]
11. FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins. Scheijen B; Ngo HT; Kang H; Griffin JD Oncogene; 2004 Apr; 23(19):3338-49. PubMed ID: 14981546 [TBL] [Abstract][Full Text] [Related]
12. Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD. Okamoto M; Hayakawa F; Miyata Y; Watamoto K; Emi N; Abe A; Kiyoi H; Towatari M; Naoe T Leukemia; 2007 Mar; 21(3):403-10. PubMed ID: 17230226 [TBL] [Abstract][Full Text] [Related]
13. Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. Brandts CH; Sargin B; Rode M; Biermann C; Lindtner B; Schwäble J; Buerger H; Müller-Tidow C; Choudhary C; McMahon M; Berdel WE; Serve H Cancer Res; 2005 Nov; 65(21):9643-50. PubMed ID: 16266983 [TBL] [Abstract][Full Text] [Related]
14. Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. Kim KT; Baird K; Ahn JY; Meltzer P; Lilly M; Levis M; Small D Blood; 2005 Feb; 105(4):1759-67. PubMed ID: 15498859 [TBL] [Abstract][Full Text] [Related]
15. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. O'Farrell AM; Abrams TJ; Yuen HA; Ngai TJ; Louie SG; Yee KW; Wong LM; Hong W; Lee LB; Town A; Smolich BD; Manning WC; Murray LJ; Heinrich MC; Cherrington JM Blood; 2003 May; 101(9):3597-605. PubMed ID: 12531805 [TBL] [Abstract][Full Text] [Related]
17. Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients. Andersson A; Johansson B; Lassen C; Mitelman F; Billström R; Fioretos T Eur J Haematol; 2004 May; 72(5):307-13. PubMed ID: 15059064 [TBL] [Abstract][Full Text] [Related]
18. Internal tandem duplications of the FLT3 and MLL genes are mainly observed in atypical cases of therapy-related acute myeloid leukemia with a normal karyotype and are unrelated to type of previous therapy. Christiansen DH; Pedersen-Bjergaard J Leukemia; 2001 Dec; 15(12):1848-51. PubMed ID: 11753604 [TBL] [Abstract][Full Text] [Related]
19. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Yamamoto Y; Kiyoi H; Nakano Y; Suzuki R; Kodera Y; Miyawaki S; Asou N; Kuriyama K; Yagasaki F; Shimazaki C; Akiyama H; Saito K; Nishimura M; Motoji T; Shinagawa K; Takeshita A; Saito H; Ueda R; Ohno R; Naoe T Blood; 2001 Apr; 97(8):2434-9. PubMed ID: 11290608 [TBL] [Abstract][Full Text] [Related]
20. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms]. Müller-Tidow C; Steur C; Mizuki M; Schwäble J; Brandts C; Berdel WE; Serve H Dtsch Med Wochenschr; 2002 Oct; 127(42):2195-200. PubMed ID: 12397548 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]